Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 55.64M.
Undervalued
The company’s latest PE is -10.27, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 14.11M shares, decreasing 11.99% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 681.62K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.96.